SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: luckydog88 who wrote (63122)5/28/2025 10:34:55 PM
From: stockdoc779 Recommendations

Recommended By
erickerickson
erippetoe
idahoranch1
jargonweary
jhcimmu

and 4 more members

  Read Replies (2) of 63284
 
I heard that new guy at FDA that spooked everyone (Prasad) about SRPT was interviewed by Goldman Sachs yesterday and was point blank asked if FDA was going to pull Elevydis approval. He stated that was not going to happen and that the FDA is looking forward and not going to revisit prior approvals. Don't think this has filtered into the market's consciousness yet. Meanwhile, SRPT had positive results in their registration trial for gene therapy for limb girdle muscular dystrophy, and Roche filed last year for European approval for Elevydis with a ruling expected before year end. The stock is trading at less than 2x revenue, it is fantastically undervalued, I would buy more but it's 10% of my portfolio at this price so I'm just going to hold my stake.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News